Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that decreases acid production in the stomach.
## Primary Indications
* Healing of erosive esophagitis
* Maintenance of healing of erosive esophagitis
* Symptomatic gastroesophageal reflux disease (GERD)
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome
## Adult Dosing
* **Healing of Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **Symptomatic GERD:** 40 mg orally once daily for up to 4 weeks.
* **Pathological Hypersecretory Conditions:** 40 mg orally or intravenously twice daily initially. Doses may be increased to 80 mg intravenously or orally twice daily.
## Pediatric Dosing
* **Age 5 to 11 years:**
* **Healing of Erosive Esophagitis:** 20 mg orally once daily for 4 to 8 weeks.
* **Symptomatic GERD:** 20 mg orally once daily for 4 weeks.
* **Age 12 to 17 years:**
* **Healing of Erosive Esophagitis:** 40 mg orally once daily for 4 to 8 weeks.
* **Symptomatic GERD:** 40 mg orally once daily for 4 weeks.
*Note: Dosing for pediatric patients below 5 years of age is not established.*
## Dose Adjustments
No dose adjustment is generally required for renal or hepatic impairment, though caution is advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, flatulence.
Less Common: Dizziness, blurred vision, rash, liver enzyme elevations.
Long-term use (typically >1 year) may be associated with:
* **Fractures:** Increased risk of osteoporosis-related fractures of the hip, wrist, or spine.
* **Clostridium difficile-associated diarrhea (CDAD):** PPIs may increase the risk.
* **Vitamin B12 Deficiency:** Reduced absorption due to decreased gastric acid.
* **Hypomagnesemia:** Can be severe and may lead to neuromuscular or cardiac effects.
* **Fundic Gland Polyps:** Benign, typically reversible upon discontinuation.
## Key Drug Interactions
* **Drugs Dependent on Gastric pH for Absorption:** Pantoprazole can decrease absorption of drugs requiring acidic environment (e.g., ketoconazole, itraconazole, certain HIV protease inhibitors like atazanavir and nelfinavir, iron salts).
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Concurrent use with clopidogrel may reduce clopidogrel's antiplatelet effect.
## Monitoring
* Monitor for signs and symptoms of vitamin B12 deficiency and hypomagnesemia, especially with prolonged therapy (>3 months).
* Monitor for bone fractures, particularly in patients at risk for osteoporosis.
* Consider monitoring magnesium levels periodically and as clinically indicated.
## Clinical Pearls
* For oral administration, pantoprazole delayed-release tablets should be swallowed whole and not chewed or crushed.
* Intravenous administration requires reconstitution and further dilution.
* The risk of bone fractures increases with higher doses and longer duration of use. Consider the lowest effective dose for the shortest duration necessary.
* Consider alternative agents for patients on clopidogrel if clinically appropriate due to potential interaction.
---
*This information is intended for healthcare professionals. Always verify current prescribing information with the official drug label or a reliable drug information resource.*
